HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Thus, in a search for the most efficient radiosensitizing strategy for clinical applications, we selected for in vivo validation the HDAC inhibitor SAHA (vorinostat), which is approved by the Food and Drug Administration for the treatment of cutaneous T-cell lymphoma patients (32).